Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.53)
# 1,050
Out of 5,123 analysts
97
Total ratings
46.15%
Success rate
6.91%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $5.65 | +413.27% | 2 | Feb 3, 2026 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.69 | +93.32% | 7 | Jan 26, 2026 | |
| CRMD CorMedix | Maintains: Buy | $18 → $13 | $7.56 | +71.96% | 5 | Jan 23, 2026 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $6 | $1.23 | +389.80% | 3 | Jan 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $7.04 | +42.05% | 4 | Jan 9, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $46 → $60 | $47.41 | +26.57% | 8 | Jan 9, 2026 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Buy | $20 | $13.47 | +48.48% | 2 | Jan 9, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $11.41 | +84.05% | 3 | Jan 9, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $1.16 | +848.28% | 4 | Jan 9, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $8.30 | +44.58% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $11.33 | +253.05% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.79 | +346.93% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $22.99 | +160.98% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.95 | +310.26% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $0.99 | +809.00% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.18 | +751.06% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $81.60 | +48.28% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $9.49 | +89.71% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.35 | +55.67% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.14 | +189.86% | 2 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.38 | +196.80% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.42 | +189.86% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $8.64 | +200.93% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.03 | +385.44% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $3.09 | +6,372.49% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $10.69 | +49.67% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $8.30 | +5,381.93% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $20.05 | +194.26% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $165.42 | +8.81% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.34 | +9,301.71% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $34.24 | -6.53% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.05 | +2,095,138.10% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $11.53 | +333.84% | 1 | Jul 12, 2018 |
Sagimet Biosciences
Feb 3, 2026
Reiterates: Buy
Price Target: $29
Current: $5.65
Upside: +413.27%
MannKind
Jan 26, 2026
Reiterates: Buy
Price Target: $11
Current: $5.69
Upside: +93.32%
CorMedix
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.56
Upside: +71.96%
Heron Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.23
Upside: +389.80%
Xeris Biopharma Holdings
Jan 9, 2026
Reiterates: Buy
Price Target: $10
Current: $7.04
Upside: +42.05%
Collegium Pharmaceutical
Jan 9, 2026
Reiterates: Buy
Price Target: $46 → $60
Current: $47.41
Upside: +26.57%
Enanta Pharmaceuticals
Jan 9, 2026
Reiterates: Buy
Price Target: $20
Current: $13.47
Upside: +48.48%
Trevi Therapeutics
Jan 9, 2026
Reiterates: Buy
Price Target: $21
Current: $11.41
Upside: +84.05%
Rani Therapeutics Holdings
Jan 9, 2026
Reiterates: Buy
Price Target: $11
Current: $1.16
Upside: +848.28%
Eupraxia Pharmaceuticals
Jan 9, 2026
Reiterates: Buy
Price Target: $12
Current: $8.30
Upside: +44.58%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $11.33
Upside: +253.05%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.79
Upside: +346.93%
Dec 3, 2025
Initiates: Buy
Price Target: $60
Current: $22.99
Upside: +160.98%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.95
Upside: +310.26%
Dec 1, 2025
Reiterates: Buy
Price Target: $9
Current: $0.99
Upside: +809.00%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.18
Upside: +751.06%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $81.60
Upside: +48.28%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $9.49
Upside: +89.71%
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $8.35
Upside: +55.67%
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.14
Upside: +189.86%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $4.38
Upside: +196.80%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.42
Upside: +189.86%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $8.64
Upside: +200.93%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.03
Upside: +385.44%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $3.09
Upside: +6,372.49%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $10.69
Upside: +49.67%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $8.30
Upside: +5,381.93%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $20.05
Upside: +194.26%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $165.42
Upside: +8.81%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.34
Upside: +9,301.71%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $34.24
Upside: -6.53%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.05
Upside: +2,095,138.10%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $11.53
Upside: +333.84%